 The hypothesis is that the combination of R-mabHDI with the standard ABVD therapy in patients with late stage Stage III and Stage IV and recurrent stage Lymphocytic Predominant Hodgkins Lymphoma will have a favorable outcome on the response and progress free survival. The study is also aimed at evaluating the safety of R-mabHDI . 